Analysis of Crowd-based Financing in the European Life Sciences
Until recently, crowd-based financing was seen as tiny a niche with little impact on the financial ecosystem, but the last two years have shown both a significant increase of crowd-financed projects and a high diversity of platforms and investment models. In terms of market size, British market analysts of the University of Cambridge accounted the value of the European online alternative finance market to €3bn for 2014.
With respect to the high capital demand in the life sciences, it was only a question of time before firms jumped on the bandwagon of crowdfinancing. The BIOCOM study „Analysis of Crowd-based Financing in European Life Sciences“ investigates for the first time the relevance of this financing instrument for biotech and medical device companies.
The report was published 26 August 2015 on the occasion of the “Crowd Dialog Europe” in Helsinki and includes the following contents:
- A first overview of the most relevant crowdfinancing platforms for life science companies in Europe
- A comparision of their main characteristics with respect to its members, partners, invested capital, minimum investment sums and life science experience
- A comprehensive compilation of the legislative environment of the most important European countries (Germany, Austria, France, UK, Spain, Netherlands, Switzerland) as well as of US and Canada
- Case studies of finished crowdfinancing campaigns in the biotech and medtech field with exclusive CEO/CFO interviews from: Antabio ASA (Wiseed), Bactest Ltd (Syndicate Room); Cell Therapy Ltd (Crowdcube), EBS Technologies GmbH (Companisto); Eyebrain SARL (anaxago); Iproteos SL (Capital Cell); Riboxx GmbH (Seedmatch)
If you are interested in the full report, please use the form below or send us an e-mail at s.wirsching[at]biocom.de.